An international clinical trial found that a combination of two cancer drugs helped certain patients live longer. But eligibility, serious side effects and the difference between approved and experimental treatments matter.
For someone diagnosed with bladder cancer that has grown into the muscle of the bladder wall, treatment decisions can be difficult. Surgery may involve removing the entire bladder, and some patients cannot tolerate the chemotherapy commonly given before that operation.
An international clinical trial offers encouraging news for those patients.
Researchers found that combining two drugs before surgery, followed by immunotherapy afterward, improved survival among people with muscle-invasive bladder cancer who could not receive or chose not to receive cisplatin-based chemotherapy.
But the findings do not mean the treatment is right for everyone. And another drug combination is already FDA-approved for certain patients in this group.
What did the bladder cancer study find?
The phase 3 VOLGA trial included 695 patients across 25 countries. Its findings were published October 24 in the New England Journal of Medicine, and UCLA Health highlighted the results on November 9.
Patients were randomly assigned to three groups. One received durvalumab and enfortumab vedotin before surgery, followed by durvalumab afterward. Another received those drugs plus a third medication. The comparison group underwent bladder-removal surgery, with approved postoperative treatment permitted.
At two years, an estimated 78.4% of patients in the two-drug group were alive, compared with 69.4% in the comparison group.
That’s a difference of nine percentage points.
Researchers also reported a 42% lower relative hazard of death during follow-up. That is a statistical comparison between groups, not a prediction of an individual patient’s outcome.
The two-drug regimen also improved event-free survival, which measures outcomes including cancer progression, recurrence and death.
The trial was funded by AstraZeneca, the manufacturer of durvalumab. Its findings were published in a peer-reviewed medical journal, but industry sponsorship remains important context.
Who might benefit?
The trial focused on patients with muscle-invasive bladder cancer who were candidates for bladder-removal surgery but could not receive or declined cisplatin-based chemotherapy.
Muscle-invasive cancer has grown into the bladder’s muscular wall. It differs from cancer confined to the inner lining.
Cisplatin may be unsuitable for patients with certain kidney problems, hearing loss, nerve damage or other health conditions.
The findings address a particular treatment gap. They do not establish benefits for everyone with bladder cancer.
Eligibility depends on cancer stage, overall health and other medical factors.
So in a new rectal cancer treatment and who qualifies?, promising cancer therapies often apply to carefully defined groups.
How does the combination work?
Enfortumab vedotin is an antibody-drug conjugate that targets a protein commonly found on bladder cancer cells and delivers a cancer-killing medication.
Durvalumab is an immunotherapy that helps the immune system recognize and attack cancer.
In VOLGA, patients received both drugs before surgery, then continued durvalumab alone afterward.
The treatment schedule matters when comparing options, but the trial did not establish that every patient would experience fewer side effects or lower costs.
What are the risks?
The survival improvement came with substantial treatment risks.
In the published study, 71.1% of patients in the two-drug group experienced a grade 3 or higher adverse event from any cause, compared with 50.2% in the control group.
These are severe medical events, but not all were necessarily caused by the drugs.
Severe events considered treatment-related occurred in 30.7% of the two-drug group. Researchers reported one treatment-related death in that group.
Potential drug risks include nerve problems, skin reactions, abnormal blood sugar and immune-related inflammation.
Side effects can affect whether patients complete treatment. You should also read about how patients can seek help when cancer treatment side effects become difficult to manage.
Patients should discuss their individual risks with their oncology team.
Is the treatment available now?
The FDA approved a different combination in November 2025: enfortumab vedotin with pembrolizumab, another immunotherapy, for certain patients with muscle-invasive bladder cancer who cannot receive cisplatin.
That approved regimen includes treatment before and after bladder-removal surgery.
VOLGA studied enfortumab vedotin with durvalumab, not pembrolizumab. The two regimens have not been directly compared in a randomized trial, so their results cannot establish which is better.
In September 2026, AstraZeneca announced FDA priority review for the VOLGA combination, with a decision expected before year’s end. A subsequent decision for that exact regimen could not be independently confirmed during Parriva’s November 9 review.
Priority review is not approval. Patients should ask their oncologist to verify the current regulatory status and discuss available treatments.
Insurance coverage and out-of-pocket costs also require individual verification. Families concerned about expenses can consult Parriva’s guide to medical debt and assistance in California.
Patients should not delay established treatment while awaiting a regulatory decision without consulting their doctors.
What should patients ask their oncologist?
Five questions can help guide the conversation:
- Am I eligible for cisplatin chemotherapy? If not, why?
- Does my cancer stage and health resemble the patients studied in VOLGA?
- Which approved treatments are appropriate for me now?
- How do the possible survival benefits compare with the side effects in my situation?
- How do the approved pembrolizumab combination and the VOLGA regimen differ, and what would insurance cover?
The VOLGA findings represent meaningful progress for patients facing difficult decisions. They also show why promising results need careful interpretation.
The next step is an informed discussion with a cancer care team about what the evidence means for an individual patient.
